Document:

Exhibit 10.6

 

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT

 

THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT
(as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated
as of [      ], 2021, is entered into by and between Future Health ESG Corp., a Delaware corporation (the “Company”),
and [     ], a [      ] (the “Purchaser”).

 

WHEREAS, the Company intends to consummate an initial
public offering of the Company’s units (the “Public Offering”), each unit consisting of one share of common
stock of the Company, par value $0.0001 per share (a “Share”), and one-half of one redeemable warrant, each
whole warrant entitling the holder to purchase one Share at an exercise price of $11.50 per Share, as set forth in the Company’s
Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “Registration Statement”),
under the Securities Act of 1933, as amended (the “Securities Act”).

 

WHEREAS, the Purchaser has agreed to purchase,
at a price of $1.00 per warrant, an aggregate of 1,000,000 warrants (or up to 1,150,000 warrants if the underwriters in the Public Offering
exercise their over-allotment option in full) (the “Private Placement Warrants”), each Private Placement Warrant
entitling the holder to purchase one Share at an exercise price of $11.50 per Share.

 

NOW THEREFORE, in consideration of the mutual promises
contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties to this Agreement hereby, intending legally to be bound, agree as follows:

 

AGREEMENT

 

Section 1.              
Authorization, Purchase and Sale; Terms of the Private Placement Warrants.

 

A.               
Authorization of the Private Placement Securities. The Company has duly authorized the issuance and sale of the Private
Placement Warrants and, subject to proper exercise of the Private Placement Warrants and against payment therefor, the Shares underlying
such Private Placement Warrants, to the Purchaser.

 

B.                
Purchase and Sale of the Private Placement Warrants.

 

(i)                 On
the date of the consummation of the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and
the Company (the “IPO Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser
shall purchase from the Company, 1,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant for an
aggregate purchase price of $1,000,000 (the “Purchase Price”). The Purchaser shall pay, at least one (1)
business day prior to the IPO Closing Date, an amount equal to the Purchase Price by wire transfer of immediately available funds to
accounts designated by the Company, including to the trust account (the “Trust Account”), at a financial
institution to be chosen by the Company, maintained by Continental Stock Transfer & Trust Company, acting as trustee, in
accordance with the Company’s wiring instructions.  On the IPO Closing Date, subject to receipt of funds pursuant to the
immediately prior sentences, the Company shall effect such delivery in book-entry form.

 

     

     

    

 

(ii)             
On the date of the consummation of the closing of the over-allotment option, if any, in connection with the Public Offering or
on such earlier time and date as may be mutually agreed by the Purchaser and the Company (an “Over-allotment Closing Date,”
and each Over-allotment Closing Date (if any) and the IPO Closing Date, a “Closing Date”), the Company shall
issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, up to 150,000 Private Placement Warrants (or, to the
extent the over-allotment option is not exercised in full, a lesser number of Private Placement Warrants in proportion to the portion
of the over-allotment option that is then exercised) at a price of $1.00 per Private Placement Warrant for an aggregate purchase price
of up to $150,000 (if the over-allotment option is exercised in full) (the “Over-allotment Purchase Price”).
The Purchaser shall pay the Over-allotment Purchase Price in accordance with the Company’s wire instruction by wire transfer of
immediately available funds to the Company or the Trust Account (as set forth in the wire instructions), at least one (1) business day
prior to the applicable Over-allotment Closing Date. On each Over-allotment Closing Date, subject to receipt of funds pursuant to the
immediately prior sentence, the Company shall effect such delivery in book-entry form.

 

C.                
Terms of the Private Placement Warrants.

 

(i)                
The Private Placement Warrants are substantially identical to the Warrants included in the units to be offered in the Public Offering
except that (a) the Private Placement Warrants will not, except in limited circumstances, be transferable or salable until 30 days after
the completion of the Company’s initial business combination (the “Business Combination”) so long as they
are held by the Purchaser or its permitted transferees, and (b) the Private Placement Warrants are being purchased pursuant to an exemption
from the registration requirements of the Securities Act and will become freely tradable only after the expiration of the lockup described
above in clause (a) and they are registered pursuant to the Registration Rights Agreement (as defined below) or an exemption from registration
is available, and the restrictions described above in clause (a) have expired, and (c) each Private Placement Warrant shall have the terms
set forth for private placement warrants in a Warrant Agreement to be entered into by the Company and a warrant agent in connection with
the Public Offering (the “Warrant Agreement”).

 

(ii)             
On or prior to the IPO Closing Date, the Company and the Purchaser shall enter into a registration rights agreement (the “Registration
Rights Agreement”) pursuant to which the Company will grant certain registration rights to the Purchaser relating to the
Private Placement Warrants and the Shares underlying the Private Placement Warrants.

 

Section 2.              
Representations and Warranties of the Company.

 

As a material inducement to the Purchaser to enter
into this Agreement and purchase the Private Placement Warrants the Company hereby represents and warrants to the Purchaser (which representations
and warranties shall survive each Closing Date) that:

 

    2 

     

    

 

A.               
 Incorporation and Corporate Power. The Company is a corporation duly incorporated, validly existing and in good standing
under the laws of the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would
reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company
possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement and the Warrant
Agreement.

 

B.                
Authorization; No Breach.

 

(i)                
The execution, delivery and performance of this Agreement and the Private Placement Warrants, and subject to proper exercise of
the Private Placement Warrants and against payment therefor, the Shares underlying such Private Placement Warrants, have been duly authorized
by the Company. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms,
subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating
to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law). Upon
issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement (as applicable) and this Agreement, the Private
Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with their terms as of each
Closing Date.

 

(ii)             
The execution and delivery by the Company of this Agreement and the Private Placement Warrants, the issuance and sale of the Private
Placement Warrants and the Shares upon exercise of the Private Placement Warrants and the fulfillment of and compliance with the respective
terms hereof and thereof by the Company, do not and will not as of each Closing Date (a) conflict with or result in a breach of the terms,
conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance
upon the Company’s share capital or assets under, (d) result in a violation of, or (e) require any authorization, consent,
approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or
agency pursuant to the Company’s certificate of incorporation (the “Charter”) and bylaws (the “Bylaws”)
or any material law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which
the Company is subject, except for any filings required after the date hereof under federal or state securities laws.

 

C.                
Title to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement
(as applicable), the Shares issuable upon exercise of the Private Placement Warrants will be duly and validly issued, fully paid and nonassessable.
On the date of issuance of the Private Placement Warrants the Shares issuable upon exercise of the Private Placement Warrants shall have
been reserved for issuance. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement (as
applicable), the Purchaser will have good title to the Private Placement Warrants and the Shares issuable upon exercise of the Private
Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions hereunder and
under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims
or encumbrances imposed due to the actions of the Purchaser.

 

    3 

     

    

 

D.               
 Governmental Consents. Assuming the accuracy of the representations and warranties made by the Purchaser in this Agreement,
no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated
by this Agreement, except for applicable requirements of the Securities Act.

 

Section 3.              
Representations and Warranties of the Purchaser.

 

As a material inducement to the Company to enter
into this Agreement and issue and sell the Private Placement Warrants to the Purchaser, the Purchaser hereby represents and warrants to
the Company (which representations and warranties shall survive each Closing Date) that:

 

A.               
Organization and Requisite Authority. The Purchaser possesses all requisite power and authority necessary to carry out the
transactions contemplated by this Agreement.

 

B.                
Authorization; No Breach.

 

(i)                
This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting
creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law).

 

(ii)             
The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the
Purchaser do not and shall not as of each Closing Date (a) conflict with or result in a breach by the Purchaser of the terms, conditions
or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon
the Purchaser’s equity or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption
or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or agency pursuant to
the Purchaser’s organizational documents in effect on the date hereof or as may be amended prior to completion of the contemplated
Public Offering, or any material law, statute, rule or regulation to which the Purchaser is subject, or any agreement, instrument, order,
judgment or decree to which the Purchaser is subject, except for any filings required after the date hereof under federal or state securities
laws.

 

C.                
Investment Representations.

 

(i)                
The Purchaser is acquiring the Private Placement Warrants, and, upon exercise of the Private Placement Warrants, the Shares issuable
upon such exercise (collectively, the “Securities”) for its own account, for investment purposes only and not
with a view towards, or for resale in connection with, any public sale or distribution thereof.

 

(ii)              The
Purchaser understands that the Securities are being offered and will be sold to it in reliance on specific exemptions from the
registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and
accuracy of, and the Purchaser’s compliance with, the representations and warranties of the Purchaser set forth herein in
order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities.

 

    4 

     

    

 

(iii)           
The Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities
Act, and the Purchaser has not experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities
Act. The Purchaser did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the
meaning of Rule 502(c) of Regulation D under the Securities Act.

 

(iv)            
The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity
to ask questions of the executive officers and directors of the Company. The Purchaser understands that its investment in the Securities
involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed
investment decision with respect to the acquisition of the Securities.

 

(v)              
The Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed
on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the
Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(vi)            
The Purchaser understands that: (a) the Securities have not been and are not being registered under the Securities Act or any state
securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold
in reliance on an exemption therefrom; (b) except as specifically set forth in the Registration Rights Agreement, neither the Company
nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply
with the terms and conditions of any exemption thereunder; and (c) Rule 144 adopted pursuant to the Securities Act will not be available
for resale transactions of Securities prior to a Business Combination and may not be available for resale transactions of Securities after
a Business Combination.

 

(vii)         
The Purchaser has such knowledge and experience in financial and business matters, knowledge of the high degree of risk associated
with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and
risks of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated
hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies
and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities. The
Purchaser can afford a complete loss of its investments in the Securities.

 

(viii)       
The Purchaser understands that the Private Placement Warrants shall bear the legend substantially in the form set forth in the
Warrant Agreement and be subject to appropriate “stop transfer restrictions”.

 

    5 

     

    

 

Section 4.              
Conditions of the Purchaser’s Obligations.

 

The obligations of the Purchaser to purchase and
pay for the Private Placement Warrants are subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

 

A.               
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and
correct at and as of such Closing Date as though then made.

 

B.                
Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by it on or before such Closing Date.

 

C.                
No Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this
Agreement or the Warrant Agreement.

 

D.               
Warrant Agreement and Registration Rights Agreement. The Company shall have entered into the Warrant Agreement and the Registration
Rights Agreement, in each case on terms satisfactory to the Purchaser.

 

Section 5.              
Conditions of the Company’s Obligations.

 

The obligations of the Company to the Purchaser
under this Agreement are subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

 

A.               
Representations and Warranties. The representations and warranties of the Purchaser contained in Section 3 shall be true
and correct at and as of such Closing Date as though then made.

 

B.                
Performance. The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by the Purchaser on or before such Closing Date.

 

C.                
Corporate Consents. The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery
and performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants, hereunder.

 

D.               
No Injunction. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this
Agreement or the Warrant Agreement.

 

    6 

     

    

 

E.                
 Warrant Agreement. The Company shall have entered into the Warrant Agreement.

 

Section 6.              
Termination.

 

This Agreement may be terminated at any time after
[●], 2021 upon the election by either the Company or the Purchaser upon written notice to the other party if the closing of the
Public Offering has not occurred prior to such date.

 

Section 7.              
Survival of Representations and Warranties.

 

All of the representations and warranties contained
herein shall survive the applicable Closing Date.

 

Section 8.              
Definitions.

 

Terms used but not otherwise defined in this Agreement
shall have the meaning assigned to such terms in the Registration Statement.

 

Section 9.              
Miscellaneous.

 

A.               
Restrictions on Transfer; Forfeiture. The Purchaser agrees that it shall not sell, transfer, assign, pledge or hypothecate
any of the Private Placement Warrants or the Shares underlying the Private Placement Warrants, or subject any of such securities to any
hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such securities,
except as provided in FINRA Rule 5110(e)(2), during the period commencing on the effective date of the Public Offering and ending 180
days after such date. Additionally, the Purchaser agrees that it will forfeit for cancellation any Private Placement Warrants held by
it on the five-year anniversary of the effective date of the Public Offering in accordance with FINRA Rule 5110(g).

 

B.                
Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement
by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether
so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other
than assignments by the Purchaser to affiliates thereof (including, without limitation one or more of its members).

 

C.                
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such
provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

D.               
Counterparts. This Agreement may be executed simultaneously in two or more counterparts, none of which need contain the
signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. Signatures to
this Agreement transmitted via facsimile or e-mail shall be valid and effective to bind the party so signing.

 

    7 

     

    

 

E.                
Descriptive Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do
not constitute a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of
example rather than by limitation.

 

F.                 
Governing Law. This Agreement shall be deemed to be a contract made under the laws of the State of New York and for all
purposes shall be construed in accordance with the internal laws of the State of New York.

 

G.               
Amendments. This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument
executed by the parties hereto.

 

[Signature page follows]

 

    8 

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Agreement to be effective as of the date first set forth above.

 

	 	COMPANY:
	 	 
	 	FUTURE HEALTH ESG CORP.
	 	 
	 	By:	                                                         
	 	 	Name: Travis A. Morgan
	 	 	Title: Chief Financial Officer
	 	 
	 	PURCHASER:
	 	 
	 	[            ]
	 	 
	 	By:	                         
	 	 	Name:
	 	 	Title:

 

[Signature Page to Private Placement
Warrants Purchase Agreement]Exhibit 10.7

 

AMENDMENT TO 

SECURITIES SUBSCRIPTION AGREEMENT

 

This Amendment (the “Amendment”)
to the Securities Subscription Agreement, dated as of March 3, 2021 (the “Agreement”), by and between Future Health
ESG Corp., a Delaware corporation (the “Company”), and [     ] (the “Subscriber”
and, together with the Company, the “Parties”), is made and entered into by the Parties as of [     ],
2021 (the “Effective Date”).

 

WHEREAS, the Parties desire
to amend the Agreement as hereinafter set forth.

 

NOW, THEREFORE, the Parties,
in consideration of the agreements and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties, intending to be legally bound hereby, do mutually agree as follows:

 

1.            Capitalized
Terms. Any capitalized terms not defined in this Amendment shall have the meaning ascribed to such term in the Agreement.

 

2.          Amendment.
As of the Effective Date, Section 3.1 of the Agreement shall be deemed deleted and replaced in its entirety with the following:

 

“Section 3.1     Partial
or No Exercise of the Over-allotment Option. In the event the over-allotment option granted to the underwriters of the IPO (as defined
below) (the “Over-allotment Option”) is not exercised in full, the Subscriber acknowledges and agrees that it (or,
if applicable, it and any transferees of Securities) shall automatically forfeit at the time such Over-allotment Option expires (or earlier
if the underwriters of the IPO waive their ability to exercise such Over-allotment Option) any and all rights to such number of Securities
(up to an aggregate of [     ] shares of Common Stock (the “Maximum Forfeited Shares”) and
pro rata based upon the percentage of the Over-allotment Option exercised). For the avoidance of doubt, the number of Securities to be
forfeited shall be equal to (i) the Maximum Forfeited Shares minus (ii) the product of (a) the Maximum Forfeited Shares
multiplied by (b) a fraction, the numerator of which is the number of Units for which the Over-allotment Option is exercised and
the denominator of which is 3,000,000 Units.”

 

3.            Effectiveness
of Agreement. This Amendment constitutes an amendment to the Agreement in accordance with the terms thereof and shall be effective
and enforceable upon all parties to the Agreement in accordance with its terms, as amended hereby. Except as amended herein, the Agreement
shall continue in full force and effect and shall be enforceable in accordance with its terms.

 

4.            Governing
Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws
that might otherwise govern under applicable principles of conflicts of law (whether of Delaware or any other jurisdiction).

 

     

     

    

 

5.            Entire
Agreement. The Agreement, as amended by this Amendment, constitutes the entire agreement between the parties relative to the specific
subject matter hereof.

 

6.            Counterparts.
This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Signature Pages Follow]

 

    2

     

    

 

IN WITNESS WHEREOF, the Parties
have caused this Amendment to be executed on this [     ] day of [     ], 2021.

 

	 	Future Health ESG Corp.

 

	 	By:	 
	 	Name:	Travis
A. Morgan
	 	Title:	CFO

 

[     ]

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

[Signature
Page to Amendment to Securities Subscription Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]